Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - This document shares information about transactions conducted by managerial staff and their close associates at Genmab A/S (Nasdaq: GMAB), in line with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) After the Annual General Meeting on March 12, 2025, Genmab's Board of Directors convened, appointing Ms. Deirdre P. Connelly as Chair and Ms. Pernille Erenbjerg as Deputy Chair. The Board decided to issue 13,926 restricted stock units and 4,214 warrants to its members and employees, with specific vesting conditions and fair values outlined. Genmab is dedicated to enhancing patient lives through innovative antibody therapies, aiming to revolutionize treatment for cancer and other serious illnesses by 2030.
Company Announcement: At Genmab A/S' Annual General Meeting on March 12, 2025, the 2024 Annual Report was approved, and the Board of Directors and Executive Management were discharged. The meeting also saw the re-election of six Board members and Deloitte as the company's auditor. Additionally, several proposals, including changes to the Remuneration Policy and a reduction in share capital, were accepted.
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has chosen not to take up its option for a global license to develop, produce, and sell HexaBody-CD38 (GEN3014). Although the early clinical results for HexaBody-CD38 are encouraging and demonstrate strong effectiveness, after careful assessment of the data, market conditions, and Genmab's strict prioritization of its projects, Genmab will not move forward with it.
Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - This document shares information about transactions conducted by managerial staff and their close associates at Genmab A/S (Nasdaq: GMAB), in line with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - This document shares information about transactions conducted by managerial staff and their close associates at Genmab A/S (Nasdaq: GMAB), in line with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will raise its share capital by 10,058 shares due to the use of employee warrants. This increase will happen without giving existing shareholders or others any preemptive rights.
Genmab announced impressive results for the fourth quarter of 2024, achieving $897.4 million in revenue, which exceeded expectations and represented a 29% year-over-year increase, mainly due to Darzalex royalties. The revenue forecast for 2025 was slightly better than what analysts predicted, and the expense forecast was unexpectedly low, suggesting only 7% growth and improving the company's financial outlook. While I anticipate that J&J will decide not to proceed with GEN3014, I remain optimistic about Genmab's product range, pipeline, and future growth opportunities.
Genmab A/S (GMAB) will hold its Q4 2024 Earnings Conference Call on February 12, 2025, at 12:00 PM ET. The call will feature key company executives, including CEO Jan van de Winkel and CFO Anthony Pagano, along with various participants from financial institutions. Please note that this conference call is being recorded.
Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab has submitted its Form 20-F for the 2024 financial year to the U.S. SEC. The company announced that this Annual Report includes sections from the Genmab A/S Annual Report 2024. You can find both reports on the SEC's website, www.sec.gov, and Genmab's website, www.genmab.com.